Australia's most trusted
source of pharma news
Wednesday, 18 June 2025
Posted 6 June 2025 AM
It appears that Illumina’s Australian workforce has been hard hit as the DNA giant looks to cut costs and mitigate losses from its Greater China business.
It’s understood that around 40 jobs have been made redundant, which means about half the local workforce has been impacted by this decision, however, the California-headquartered company neither confirmed nor denied the total number of roles cut in Australia.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.